Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 11 to 20 of 2529

TitleReference numberPublishedLast updated
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenTA259
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA387
Abortion careNG140
Abortion careQS199
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisTA814
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Accuro for guiding epidural or spinal anaesthesiaMIB245

Results per page

  1. 10
  2. 25
  3. 50
  4. All